Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”Strattmont Group
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,279,768 covering Precision’s monoclonal antibodies that directly bind to cancer-associated antigen targets.
Source: Precision Biologics, Inc.
Released: March 22, 2022